DoH Policies screened during the period: 1 January 2025 – 31 March 2025
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA1023 - Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (PDF 301KB)
- NICE Technology Appraisal TA1025 - Ublituximab for treating relapsing multiple sclerosis (PDF 277KB)
- DOH framework learning improvement (PDF 282KB)
- NICE Technology Appraisal TA1026 - Tirzepatide for managing overweight and obesity (PDF 280KB)
- NICE Clinical Guideline / Pathway NGs 244 / 245 - Asthma pathway / Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (PDF 350KB)
- NICE Technology Appraisal TA1027 - Tebentafusp for treating advanced uveal melanoma (PDF 301KB)
- NICE Technology Appraisal TA1030 - Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (PDF 278KB)
- NICE Technology Appraisal TA1031 - Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (PDF 277KB)
- - NICE Technology Appraisal TA1034 - Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (PDF 277KB)
- NICE Technology Appraisal TA1035 - Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (PDF 277KB)
- NICE Technology Appraisal TA1033 - Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (PDF 302KB)
- NICE Technology Appraisal TA1036 - Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (PDF 280KB)
- NICE Technology Appraisal TA1038 - Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (review of TA742) (PDF 279KB)
- NICE Technology Appraisal TA1037 - Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (PDF 279KB)
- NICE Technology Appraisal TA1039 - Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (PDF 279KB)
- NICE Technology Appraisal TA1040 - Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (review of TA762) (PDF 280KB)
- NICE Technology Appraisal TA1041 - Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (review of TA662) (PDF 279KB)
- Department of Health Sexual Health Action Plan (PDF 293KB)
- NICE Technology Appraisal TA1042 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (review of TA760) (PDF 297KB)
- NICE Technology Appraisal TA1043 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (review of TA761) (PDF 302KB)
- NICE Technology Appraisal TA1044 - Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (PDF 299KB)
- NICE Technology Appraisal TA1045 - 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834)
- HSC Pension Schemes (Amendment No. 2) (PDF 185KB)
- Healthy Child, Healthy Future (2025) (PDF 299KB)
- Passporting to help with health costs under Universal Credit (PDF 395KB)